Compare AER & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | ALNY |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | Ireland | United States |
| Employees | N/A | 115 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6B | 21.6B |
| IPO Year | 2006 | 2004 |
| Metric | AER | ALNY |
|---|---|---|
| Price | $167.18 | $150.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 30 |
| Target Price | $186.60 | ★ $284.96 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 10-28-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | N/A | ★ 18.42 |
| Revenue | N/A | ★ $1,037,418,000.00 |
| Revenue This Year | $6.11 | $46.31 |
| Revenue Next Year | N/A | $17.44 |
| P/E Ratio | ★ $7.27 | $8.02 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $130.12 | $146.51 |
| 52 Week High | $183.22 | $479.79 |
| Indicator | AER | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 27.15 |
| Support Level | $133.19 | N/A |
| Resistance Level | N/A | $235.28 |
| Average True Range (ATR) | 4.11 | 7.83 |
| MACD | -0.34 | 0.38 |
| Stochastic Oscillator | 36.43 | 5.30 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties. It has one business segment: leasing, financing, sales, and management of commercial flight equipment (Commercial Flight Equipment Segment). Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include China, the United States, and Other countries.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.